U.S. market Closed. Opens in 11 hours 44 minutes

FDMT | 4D Molecular Therapeutics, Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for FDMT we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is strong.

Valuation (16%)

Company Industry
P/E Ratio (TTM) -8.17 -16.22
PEG Ratio (TTM) -0.23 -1.41
P/S Ratio (TTM) 41.77 48.82
P/B Ratio (TTM) 1.53 21.13
P/FCF Ratio (TTM) -9.69 9.38
Price to 5YR AVG Earnings Ratio -6.62 -0.21
Price to 5YR AVG FCF Ratio -12.17 -7.10

Profitability (25%)

Company Industry
ROA (TTM) -17.72% -3.10%
ROE (TTM) -24.06% 24.21%
Net Profit Margin (TTM) -543.54% -1,069.78%
ROIC 5YR AVG 36.76% 16.50%

Growth (25%)

4QTR AVG 3YR AVG 5YR AVG
EPS -37.99% -61.73% -38.94%
Revenue 2,104.67% 25.60% 111.29%
Net Income -39.41% -160.62% -105.93%
Cash Flow -483.08% -66.79% -42.64%

Health (70%)

Company Industry
Current Ratio (TTM) 28.48 5.75
Quick Ratio (TTM) 28.48 5.47
D/E Ratio (TTM) 0.02 -15.13
Interest Coverage (TTM) -92.93 3.59
Piotroski F-Score 5 5
Altman Z-Score 15.36 13.47
LTL to 5YR AVG FCF -0.17 0.20
Shares Outstanding Growth 5YR AVG 30.78% 118.86%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙